Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
在NCI-MATCH试验中,克唑替尼用于携带ALK或ROS1重排的肿瘤患者
期刊:npj Precision Oncology
影响因子:8
doi:10.1038/s41698-022-00256-w
Mansfield, A S; Wei, Z; Mehra, R; Shaw, A T; Lieu, C H; Forde, P M; Drilon, A E; Mitchell, E P; Wright, J J; Takebe, N; Sharon, E; Hovelson, D; Tomlins, S; Zeng, J; Poorman, K; Malik, N; Gray, R J; Li, S; McShane, L M; Rubinstein, L V; Patton, D; Williams, P M; Hamilton, S R; Conley, B A; Arteaga, C L; Harris, L N; O'Dwyer, P J; Chen, A P; Flaherty, K T